Top Markets
#1 MowCat MowCat +526.85%
#2 龙虾 (Lobster) 龙虾 (Lobster) +87.16%
#3 Magma Finance Magma Finance +40.75%
#4 Akedo Akedo +36.23%
#5 SIXSEVEN SIXSEVEN +30.35%
#6 Cortex Cortex +25.50%
#7 DeXe DeXe +16.75%
#8 OpenEden OpenEden +16.58%
#9 Pons Pons +15.57%
#10 MarsCoin MarsCoin +13.89%
Coin of the day
MowCat MowCat
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Staidson (Beijing) BioPharmaceuticals Co., Ltd. Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Staidson (Beijing) BioPharmaceuticals Co., Ltd.

300204
Rang in Aktien #7952
Staidson (Beijing) BioPharmaceuticals Co., Ltd. is a Chinese biopharmaceutical... Staidson (Beijing) BioPharmaceuticals Co., Ltd. is a Chinese biopharmaceutical company that specializes in the entire lifecycle of therapeutic drugs, from research and development to production and market distribution. Their product portfolio encompasses a variety of drug types, including advanced protein-based medicines like therapeutic monoclonal antibodies, innovative gene and cell therapies, and conventional chemical pharmaceuticals. The company's primary therapeutic areas address conditions related to the nervous system, infectious diseases, gastrointestinal health, the urinary system, and autoimmune disorders. Notably, Staidson has established a strategic partnership with Pivotal S.L. to conduct clinical trials in Europe for BDB-001, a monoclonal anti-C5a antibody, aimed at treating patients with severe, progressive COVID-19 caused by the SARS-CoV-2 virus. Founded in 2002, the company's headquarters are located in Beijing, China.
Aktienkurs
$3.11
Marktkapitalisierung
$1.41B
Veränderung (1 Tag)
-1.97%
Veränderung (1 Jahr)
-57.22%
Land
CN
Handel Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204)

Kategorie

Healthcare
P/B-Verhältnis für Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Staidson (Beijing) BioPharmaceuticals Co., Ltd. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für Staidson (Beijing) BioPharmaceuticals Co., Ltd. von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH